



() -

*

**

()

)

()

)

(

(P> /)

(P> /)

(P< /)

(P> /)

(P< /)

(P> /)

(P< /)

()
)
(Desferal or Deferoxamine mesylate)
(.)
(.)
() Deferiprone (DFP or L) (.)
(.)
() (.)
(.)
(.)
() (Compliance)
(.) (Adherence)
(.)
()
()
() (.)
() ()
(Affective) (Cognitive)
()



/

/

)

()

(

Archive of SID

()

(Enzymatic Immunoassay)

()

Dynex Technology

/

SPSS

(SPSS Inc., Chicago, IL, USA)

(Mc Nemar)

(P> /)

(P> /) /

(/)

()

()

) /

(/)

)

(/

()

(/

()

()

()

)

()

(P< /

/

/

(/)

)

(P> /)

(P> /

(

()

()

(% /)

(% /)

(% /)*

(% /)

(% /) ζ

(% /)

(% /)*

(% /)

(% /)

(% /)

(% /)*

(% /)

(% /)

(% /)

(% /)

(% /)

ξ

P< / *
P< / ζ
ξ

(P> /)

(P> /) ()

() (/)

() () (/)

() (/) () ()

() (/) (P< /)

() (P< /) () ()

(/) () (P< /)


(P> /) () ()

() () () ()

() () () ()

() (P< /) () ()

() (P> /) () ()



()

()

()

)

()

(

()

()

()

()

Archive of SID

()

()

()

()

"
.() " (dysphonic mood)

.()

.()

.()

"
"

.()

Archive of SID

.()

.()

.()

()

.()

(Reminder technique)

()

()

()

()

()

()

()

()

()

()

References:

۱. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. *Circulation* ۱۹۶۴; ۳۰: ۶۹۸-۷۰۵.

۲. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. *N Engl J Med* ۱۹۹۴; ۳۳۱: ۵۶۷-۷۳.

۳. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. *N Engl J Med* ۱۹۹۴; ۳۳۱: ۵۶۷-۷۳.

۴. Victor HA. Deferiprone therapy for transfusional iron overload. *Best Pract Res Clin Haematol* ۲۰۰۵; ۱۸: ۲۹۹-۳۱۷.

۵. Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. *Pediatr Blood Cancer* ۲۰۰۵; ۴۴: ۵۰۰-۷.

۶. Porter JB. A risk-benefit assessment of iron-chelation therapy. *Drug Saf* ۱۹۹۷; ۱۷: ۴۰۷-۲۱.

۷. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. *Hematology (Am Soc Hematol Educ Program)* ۲۰۰۱; ۱: ۴۷-۶۱.

۸. Meo A, Ruggeri A, La Rosa MA, et al. Long-term treatment with deferiprone in a L¹ veteran. *Eur J Haematol*. ۲۰۰۵; ۷۴: ۵۲۳-۵.

۹. Porter JB, Abeyasinghe RD, Marshall L, et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy. *Blood* ۱۹۹۶; ۸۸: ۷۰۵-۱۴.

۱۰. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. *Eur J Haematol* ۲۰۰۵; ۷۴: ۲۱۷-۲۰.
۱۱. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. *JAMA* ۲۰۰۲; ۲۸۸: ۲۸۸-۲.
۱۲. Puckett MJ, Russell ML. The role of the allied health professional in improving patient adherence. *J Allied Health* ۱۹۷۸; ۷: ۳۶-۴۱.
۱۳. Willey C. Behavior-changing methods for improving adherence to medication. *Curr Hypertens Rep* ۱۹۹۹; ۱: ۴۷۷-۸۱.
۱۴. Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. *Semin Hematol* ۲۰۰۱; ۳۸ Suppl ۱: ۷۷-۸۴.
۱۵. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. *J Am Pharm Assoc* ۲۰۰۳; ۴۳: ۶۶۸-۷۸.
۱۶. Burke LE, Dunbar-Jacob J. Adherence to medication, diet, and activity recommendations: from assessment to maintenance. *Cardiovasc Nurs* ۱۹۹۵; ۹: ۶۲-۷۹.
۱۷. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. *JAMA* ۲۰۰۲; ۲۸۸: ۲۸۶۸-۷۹.
۱۸. Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. *Annu Rev Nurs Res* ۲۰۰۰; ۱۸: ۴۸-۹۰.
۱۹. Sherman M, Koch D, Giardina P, et al. Thalassaemic children's understanding of illness: a study of cognitive and emotional factors. *Ann NY Acad Sci* ۱۹۸۵; ۴۴۵: ۳۲۷-۳۶.
۲۰. Schaffer SD, Yoon SJ. Evidence-based methods to enhance medication adherence. *Nurse Pract* ۲۰۰۱; ۲۶: ۴۴, ۵۰, ۵۲, ۵۴.
۲۱. Angastiniotis M. The adolescent thalassaemic. The complicant rebel. *Minerva Pediatr* ۲۰۰۲; ۵۴: ۵۱۱-۵.
۲۲. Goldbeck L, Baving A, Kohne E. Psychosocial aspects of beta-thalassemia: distress, coping and adherence. *Klin Padiatr* ۲۰۰۰; ۲۱۲: ۲۵۴-۹.
۲۳. Koch DA, Giardina PJ, Ryan M, et al. Behavioral contracting to improve adherence in patients with thalassemia. *J Pediatr Nurs* ۱۹۹۳; ۸: ۱۰۶-۱۱.
۲۴. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. *BMC Clin Pharmacol* ۲۰۰۲; ۲: ۳. <http://www.biomedcentral.com/۱۴۷۲-۶۹۰۴/۲/۳>
۲۵. Linda Carman Copel. Health education and promotion. In: Suzanne C. Smeltzer, Brenda G. Bare. Brunner & Suddarth's Textbook of Medical-Surgical Nursing. ۹th ed. Philadelphia: J.B Lippincott Co, ۲۰۰۰, ۴۰-۵۰.
۲۶. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. *N Engl J Med* ۲۰۰۰; ۳۴۳: ۳۲۷-۳۱.
۲۷. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. *Am J Hematol* ۱۹۹۳; ۴۲: ۸۱-۵.
۲۸. Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. *Eur J Haematol* ۲۰۰۵; ۷۴: ۹۳-۱۰۰.
۲۹. van Oost BA, van den Beld B, Cloin LG, et al. Measurement of ferritin in serum: application in diagnostic use. *Clin Biochem* ۱۹۸۴; ۱۷: ۲۶۳-۹.